Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company, today announced that two posters and one oral presentation related to the Company’s lead product candidate, VIS410, a novel monoclonal antibody in development for the treatment of seasonal and pandemic influenza A, will be presented at the Options IX for the Control of Influenza Conference in Chicago, Illinois, on August 24 – 28, 2016.